{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:14:07Z","timestamp":1781576047219,"version":"3.54.5"},"reference-count":54,"publisher":"Impact Journals, LLC","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,9,26]]},"DOI":"10.18632\/oncotarget.18359","type":"journal-article","created":{"date-parts":[[2017,6,4]],"date-time":"2017-06-04T05:00:34Z","timestamp":1496552434000},"page":"73654-73669","source":"Crossref","is-referenced-by-count":32,"title":["Active evolution of memory B-cells specific to viral gH\/gL\/pUL128\/130\/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection"],"prefix":"10.18632","volume":"8","author":[{"given":"Lin","family":"Xia","sequence":"first","affiliation":[{"name":"Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA"},{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Tang","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixu","family":"Meng","sequence":"additional","affiliation":[{"name":"Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Freed","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linling","family":"He","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Wang","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengsheng","family":"Li","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leike","family":"Li","sequence":"additional","affiliation":[{"name":"Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[{"name":"Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Gui","sequence":"additional","affiliation":[{"name":"Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbie D.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotai","family":"Chen","sequence":"additional","affiliation":[{"name":"Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"He","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Swoyer","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Ha","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Liu","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinjian","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Luo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Espeseth","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria J.","family":"Hazuda","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Rupp","sequence":"additional","affiliation":[{"name":"Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA"},{"name":"Center for HIV\/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA, USA"},{"name":"Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-Ming","family":"Fu","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"An","sequence":"additional","affiliation":[{"name":"Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA"},{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,6,3]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/rmv.659","article-title":"Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"key":"2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1086\/314939","article-title":"Asymptomatic primary cytomegalovirus infection: virologic and immunologic features","volume":"180","author":"Pass","year":"1999","journal-title":"J Infect Dis"},{"key":"3","unstructured":"Mocarski, Shenk, Pass. (2007). Cytomegalovirus. In: Knipe D, Howley P, Griffin D, Martin M, Lamb R, Roiz-man B and Straus S, eds. Fields Virology: Lippincott Williams & Wilkins), pp. 2701-72."},{"key":"4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of human cytomegalovirus: from bench to bedside","volume":"22","author":"Khanna","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1086\/649903","article-title":"Cytomegalovirus reinfections in healthy seroimmune women","volume":"201","author":"Boppana","year":"2010","journal-title":"J Infect Dis"},{"key":"6","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1056\/NEJM200105033441804","article-title":"Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity","volume":"344","author":"Britt","year":"2001","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1586\/eci.12.25","article-title":"Immune response to CMV in solid organ transplant recipients: current concepts and future directions","volume":"8","author":"Razonable","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"8","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: pathogen, paradigm, and puzzle","volume":"121","author":"Geballe","year":"2011","journal-title":"J Clin Invest"},{"key":"9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Cannon","year":"2007","journal-title":"Rev Med Virol"},{"key":"10","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Atkinson","year":"2011","journal-title":"Lancet"},{"key":"11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.vaccine.2013.09.042","article-title":"Priorities for CMV vaccine development","volume":"32","author":"Plotkin","year":"2013","journal-title":"Vaccine"},{"key":"12","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.vaccine.2014.03.057","article-title":"Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease","volume":"32","author":"Wang","year":"2014","journal-title":"Vaccine"},{"key":"13","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","article-title":"Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy","volume":"12","author":"Milne","year":"2012","journal-title":"Am J Transplant"},{"key":"14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/infdis\/171.1.26","article-title":"Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age","volume":"171","author":"Best","year":"1995","journal-title":"J Infect Dis"},{"key":"15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM199203053261003","article-title":"The outcome of congenital cytomegalovirus infection in relation to maternal antibody status","volume":"326","author":"Alford","year":"1992","journal-title":"N Engl J Med"},{"key":"16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jama.289.8.1008","article-title":"Maternal immunity and prevention of congenital cytomegalovirus infection","volume":"289","author":"Pass","year":"2003","journal-title":"JAMA"},{"key":"17","doi-asserted-by":"publisher","first-page":"362ra145","DOI":"10.1126\/scitranslmed.aaf9387","article-title":"A replication-defective human cytomegalovirus vaccine for prevention of congenital infection","volume":"8","author":"Finnefrock","year":"2016","journal-title":"Sci Transl Med"},{"key":"18","doi-asserted-by":"publisher","first-page":"14976","DOI":"10.1073\/pnas.2136652100","article-title":"Coding potential of laboratory and clinical strains of human cytomegalovirus","volume":"100","author":"Shenk","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Picker","year":"2005","journal-title":"J Exp Med"},{"key":"20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nri.2016.38","article-title":"T cell responses to cytomegalovirus","volume":"16","author":"Oxenius","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"21","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1111\/j.1600-6143.2006.01488.x","article-title":"Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation","volume":"6","author":"Rampino","year":"2006","journal-title":"Am J Transplant"},{"key":"22","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1182\/blood-2015-03-631853","article-title":"CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRbeta repertoire","volume":"125","author":"Cheeseman","year":"2015","journal-title":"Blood"},{"key":"23","doi-asserted-by":"publisher","first-page":"17965","DOI":"10.1073\/pnas.1415310111","article-title":"Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies","volume":"111","author":"Lanzavecchia","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"24","doi-asserted-by":"publisher","first-page":"9075","DOI":"10.1016\/j.vaccine.2011.09.056","article-title":"Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection","volume":"29","author":"Fu","year":"2011","journal-title":"Vaccine"},{"key":"25","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Feierbach","year":"2012","journal-title":"J Virol"},{"key":"26","doi-asserted-by":"publisher","first-page":"15985","DOI":"10.1074\/jbc.M115.652230","article-title":"Soluble human cytomegalovirus gH\/gL\/pUL128-131 pentameric complex, but not gH\/gL, inhibits viral entry to epithelial cells and presents dominant native neutralizing epitopes","volume":"290","author":"DePhillips","year":"2015","journal-title":"J Biol Chem"},{"key":"27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Lanzavecchia","year":"2010","journal-title":"J Virol"},{"key":"28","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.1128\/JVI.00121-16","article-title":"Monoclonal Antibodies to Different Components of the Human Cytomegalovirus (HCMV) Pentamer gH\/gL\/pUL128L and Trimer gH\/gL\/gO as well as Antibodies Elicited during Primary HCMV Infection Prevent Epithelial Cell Syncytium Formation","volume":"90","author":"Lilleri","year":"2016","journal-title":"J Virol"},{"key":"29","doi-asserted-by":"publisher","first-page":"e1005230","DOI":"10.1371\/journal.ppat.1005230","article-title":"Antigenic Characterization of the HCMV gH\/gL\/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies","volume":"11","author":"Carfi","year":"2015","journal-title":"PLoS Pathog"},{"key":"30","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.AID-0026-2014","article-title":"Histrory and practice: antibodies in infectious disease","volume":"3","author":"Hey","year":"2015","journal-title":"Microbiology Spectrum"},{"key":"31","doi-asserted-by":"publisher","first-page":"E4997","DOI":"10.1073\/pnas.1316517110","article-title":"Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"32","doi-asserted-by":"publisher","first-page":"e1002172","DOI":"10.1371\/journal.ppat.1002172","article-title":"B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies","volume":"7","author":"Winkler","year":"2011","journal-title":"PLoS Pathog"},{"key":"33","doi-asserted-by":"publisher","first-page":"7469","DOI":"10.1016\/j.vaccine.2012.10.053","article-title":"Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus","volume":"30","author":"Casimiro","year":"2012","journal-title":"Vaccine"},{"key":"34","doi-asserted-by":"publisher","first-page":"8350","DOI":"10.1016\/j.vaccine.2011.08.086","article-title":"A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines","volume":"29","author":"Fu","year":"2011","journal-title":"Vaccine"},{"key":"35","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1016\/j.vaccine.2008.07.092","article-title":"Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection","volume":"26","author":"McVoy","year":"2008","journal-title":"Vaccine"},{"key":"36","doi-asserted-by":"publisher","first-page":"18153","DOI":"10.1073\/pnas.0509201102","article-title":"Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism","volume":"102","author":"Shenk","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tcb.2003.10.009","article-title":"Receptors and immune sensors: the complex entry path of human cytomegalovirus","volume":"14","author":"Compton","year":"2004","journal-title":"Trends Cell Biol"},{"key":"38","doi-asserted-by":"publisher","first-page":"e1002905","DOI":"10.1371\/journal.ppat.1002905","article-title":"PDGF receptor-alpha does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway","volume":"8","author":"Johnson","year":"2012","journal-title":"PLoS Pathog"},{"key":"39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies","volume":"509","author":"Bailer","year":"2014","journal-title":"Nature"},{"key":"40","doi-asserted-by":"publisher","first-page":"6470","DOI":"10.1073\/pnas.1219320110","article-title":"Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy\/light chains","volume":"110","author":"Lloyd","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2013.03.018","article-title":"Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization","volume":"153","author":"Seaman","year":"2013","journal-title":"Cell"},{"key":"42","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1126\/science.1207532","article-title":"Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing","volume":"333","author":"Schmidt","year":"2011","journal-title":"Science"},{"key":"43","doi-asserted-by":"publisher","first-page":"6778","DOI":"10.1038\/srep06778","article-title":"Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding","volume":"4","author":"Zhu","year":"2014","journal-title":"Sci Rep"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01375-15","article-title":"Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis","volume":"6","author":"Zhu","year":"2015","journal-title":"MBio"},{"key":"45","doi-asserted-by":"publisher","first-page":"13627","DOI":"10.1038\/ncomms13627","article-title":"Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein","volume":"7","author":"Tortorella","year":"2016","journal-title":"Nat Commun"},{"key":"46","doi-asserted-by":"publisher","first-page":"11884","DOI":"10.1128\/JVI.01701-15","article-title":"Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH\/gL Pentamer Potently Block Primary Cytotrophoblast Infection","volume":"89","author":"Diamond","year":"2015","journal-title":"J Virol"},{"key":"47","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1086\/657412","article-title":"Cytomegalovirus viruria and DNAemia in healthy seropositive women","volume":"202","author":"Ross","year":"2010","journal-title":"J Infect Dis"},{"key":"48","article-title":"Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targets Viral gH\/gL\/pUL128-131 Pentameric Complex","volume":"13","author":"DePhilips","year":"2017","journal-title":"Journal of Virology"},{"key":"49","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.immuni.2013.04.012","article-title":"Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies","volume":"39","author":"Louder","year":"2013","journal-title":"Immunity"},{"key":"50","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature12053","article-title":"NISC Comparative Sequencing Program. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"Mullikin","year":"2013","journal-title":"Nature"},{"key":"51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Olsen","year":"2009","journal-title":"Science"},{"key":"52","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.immuni.2015.10.014","article-title":"Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design","volume":"43","author":"Burton","year":"2015","journal-title":"Immunity"},{"key":"53","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00705-005-0696-5","article-title":"Human cytomegalovirus UL131A, UL130 and UL128 genes are highly conserved among field isolates","volume":"151","author":"Gerna","year":"2006","journal-title":"Arch Virol"},{"key":"54","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1128\/JVI.64.6.2922-2931.1990","article-title":"Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne","volume":"64","author":"Pachl","year":"1990","journal-title":"J Virol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T11:22:08Z","timestamp":1589196128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,3]]},"references-count":54,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2017,9,26]]}},"alternative-id":["18359","29088734"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.18359","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,3]]}}}